UTHR - UNITED THERAPEUTICS Corp
IEX Last Trade
360.04
-3.780 -1.050%
Share volume: 0
Last Updated: Fri 27 Dec 2024 03:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-1.15%
PREVIOUS CLOSE
CHG
CHG%
$363.82
-3.78
-1.04%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-02 | 2023-02-22 | 2023-05-03 | 2023-08-02 | 2023-11-01 | 2024-02-21 | 2024-05-01 | 2024-07-31 | |
| Total revenue | 516.000 M | 491.500 M | 506.900 M | 596.500 M | 609.400 M | 614.700 M | 677.700 M | 714.900 M | |
| Cost of revenue | 37.200 M | 58.800 M | 52.300 M | 64.100 M | 70.100 M | 71.000 M | 72.900 M | 77.800 M | |
| Gross profit | 478.800 M | 432.700 M | 454.600 M | 532.400 M | 539.300 M | 543.700 M | 604.800 M | 637.100 M | |
| -9.63% | 5.06% | 17.11% | 1.30% | 0.82% | 11.24% | 5.34% | |||
| Operating expenses | 164.500 M | 257.100 M | 170.200 M | 219.000 M | 212.300 M | 283.600 M | 248.500 M | 317.200 M | |
| Selling general and admin | 98.400 M | 163.200 M | 87.300 M | 130.000 M | 127.600 M | 132.200 M | 144.400 M | 177.600 M | |
| Research and development | 66.100 M | 93.900 M | 82.900 M | 89.000 M | 84.700 M | 151.400 M | 104.100 M | 139.600 M | |
| Total expenses | 201.700 M | 315.900 M | 222.500 M | 283.100 M | 282.400 M | 354.600 M | 321.400 M | 395.000 M | |
| 56.62% | -29.57% | 27.24% | -0.25% | 25.57% | -9.36% | 22.90% | |||
| Operating income | 314.300 M | 175.600 M | 284.400 M | 313.400 M | 327.000 M | 260.100 M | 356.300 M | 319.900 M | |
| Ebit | 314.300 M | 175.600 M | 284.400 M | 313.400 M | 327.000 M | 260.100 M | 356.300 M | 319.900 M | |
| Pretax income | 312.500 M | 178.800 M | 291.900 M | 335.200 M | 351.800 M | 295.400 M | 398.600 M | 355.300 M | |
| -42.78% | 63.26% | 14.83% | 4.95% | -16.03% | 34.94% | -10.86% | |||
| Income tax | 73.200 M | 46.700 M | 51.000 M | 76.000 M | 84.200 M | 78.300 M | 92.000 M | 77.200 M | |
| Net income basic | 239.300 M | 132.100 M | 240.900 M | 259.200 M | 267.600 M | 217.100 M | 306.600 M | 278.100 M | |
| -44.80% | 82.36% | 7.60% | 3.24% | -18.87% | 41.23% | -9.30% | |||
| Net income | 239.300 M | 132.100 M | 240.900 M | 259.200 M | 267.600 M | 217.100 M | 306.600 M | 278.100 M | |
| -44.80% | 82.36% | 7.60% | 3.24% | -18.87% | 41.23% | -9.30% |